Postpublication validation of the 2010 American College of Rheumatology/European League Against Rheumatism classification criteria for rheumatoid arthritis

2013 ◽  
Vol 25 (2) ◽  
pp. 157-163 ◽  
Author(s):  
Jennifer H. Humphreys ◽  
Deborah P.M. Symmons
Keyword(s):  
Rheumatoid Arthritis ◽  
Classification Criteria ◽  
American College Of Rheumatology ◽  
European League Against Rheumatism ◽  
European League

scholarly journals DPP-4 inhibitor (sitagliptin)-induced seronegative rheumatoid arthritis

2019 ◽  
Vol 12 (8) ◽  
pp. e228981 ◽  
Author(s):  
Simonette Padron ◽  
Everett Rogers ◽  
Michelle Demory Beckler ◽  
Marc Kesselman
Keyword(s):  
Rheumatoid Arthritis ◽  
Classification Criteria ◽  
Predisposing Factor ◽  
Dipeptidyl Peptidase 4 ◽  
American College Of Rheumatology ◽  
European League Against Rheumatism ◽  
Dipeptidyl Peptidase 4 Inhibitor ◽  
Inflammatory Arthropathy ◽  
European League

Sitagliptin is a dipeptidyl peptidase-4 inhibitor commonly used in the treatment of type 2 diabetes mellitus for glycaemic control. Concerns have arisen regarding adverse events caused by this drug, particularly concerning arthralgias. Here, we report on a 56-year-old man being treated with sitagliptin who developed inflammatory arthritis after taking the drug for 6 months. The patient presented with pain, swelling and erythema in multiple joints and was eventually diagnosed with seronegative rheumatoid arthritis (RA) under the 2010 American College of Rheumatology/European League Against Rheumatism classification criteria. His symptoms continued for several months after stopping sitagliptin and eventually went into remission after a tapered course of steroids, hydroxychloroquine and methotrexate. Furthermore, the patient is HLA-DRB3 positive, a genetic marker that is still being investigated for its role in the pathogenesis of RA and that may have been a predisposing factor in the development of this patient’s inflammatory arthropathy.

Sign in / Sign up

Export Citation Format

Share Document